Latest news
Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Yahoo Finance SingaporeYahoo Finance Singapore · Thu, 06 Aug 2026 20:05:00 GMTLeerink Partners Adjusts Price Target on Waters to $450 From $420, Maintains Outperform Rating - finance.yahoo.comfinance.yahoo.com · Wed, 05 Aug 2026 11:36:53 GMTAttovia Therapeutics Announces Pricing of Upsized Initial Public Offering - Yahoo Finance SingaporeYahoo Finance Singapore · Wed, 05 Aug 2026 00:50:00 GMTLeerink Partners Adjusts Price Target on Incyte to $155 From $131, Maintains Outperform Rating - finance.yahoo.comfinance.yahoo.com · Mon, 03 Aug 2026 13:04:26 GMTLeerink Partners Adjusts Bristol-Myers Squibb Price Target to $73 From $67, Maintains Outperform Rating - finance.yahoo.comfinance.yahoo.com · Fri, 31 Jul 2026 07:00:00 GMTLeerink Partners Adjusts Price Target on IQVIA to $280 From $240, Maintains Outperform Rating - finance.yahoo.comfinance.yahoo.com · Wed, 29 Jul 2026 07:00:00 GMTLeerink Partners Adjusts Universal Health Services Price Target to $198 From $215, Maintains Outperform Rating - finance.yahoo.comfinance.yahoo.com · Wed, 29 Jul 2026 07:00:00 GMT